Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study
Summary Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting β2 -agonists (LABA) or both, necessitating additional treatment. Patients ≥18 years ( n = 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS + LAB...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2010-05, Vol.104 (5), p.644-651 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 651 |
|---|---|
| container_issue | 5 |
| container_start_page | 644 |
| container_title | Respiratory medicine |
| container_volume | 104 |
| creator | Virchow, J. Christian Mehta, Anish Ljungblad, Li Mitfessel, Harald |
| description | Summary Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting β2 -agonists (LABA) or both, necessitating additional treatment. Patients ≥18 years ( n = 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS + LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1 /PEF. Mean ACT scores improved from 14.6 ± 4.6 (baseline) to 19.4 ± 4.4 (month 6; p < 0.0001). Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively); the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma at baseline increased at month 6 (47.5 and 11.4%, respectively). The mini-AQLQ score (mean ± SD) improved from 4.0 ± 1.1 to 5.3 ± 1.1 ( p < 0.0001); FEV1 increased from 2.46 ± 0.89 to 2.60 ± 0.92 L ( p < 0.0001). Treatment with montelukast was generally well tolerated. In patients insufficiently controlled with ICS or ICS + LABAs, daily add-on montelukast improved both asthma control and asthma-related quality of life. Clinicaltrials.gov registry number NCT00802789. |
| doi_str_mv | 10.1016/j.rmed.2009.11.022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733940087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611109003862</els_id><sourcerecordid>733940087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-6e099c6081882611945c786acf53011d7f42092f023b2362f2088d50b92f01eb3</originalsourceid><addsrcrecordid>eNp9kt1q3DAQhU1paTZpX6AXRVBK2gu7I8k_ciiFZelPIG0uml4LWR6z3sj2RrIL-xB9547xpoFcFAQCne8MMzoTRa84JBx4_mGX-A7rRACUCecJCPEkWvFMilhCnj6NVlBmaZxzzk-i0xB2QGCawvPohCySSyVW0Z91XcdDz7qhH9FNtyaMrO3pmBrvJkNvB2ZJ84NzWDOSt51hezO22I9hRg3L49m9ZcMe-9iZCh0L41QfLtjNFtn36x__Kl_2bLP1Q99atl4qvSP5crN-vzheRM8a4wK-PN5n0a8vn2823-Kr669EXcU2K9QY5whlaXNQXClB85VpZguVG9tkEjiviyYVUIoGhKyEzEUjQKk6g2p-41jJs-h8qbv3w92EYdRdGyw6Z3ocpqALKcsUQBVEvnlE7obJ99Sc5iAzLqHgJVFioawfQvDY6L1vO-MPBOk5K73Tc1Z6zkpzrikrMr0-lp6qWbu33IdDwNsjYII1rvGmt2144EShSslz4j4uHNKX_W7R62ApHot169GOuh7a__fx6ZHdupYiMu4WDxge5tVBaNA_562alwpKalTlQv4FP1vEvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1035130719</pqid></control><display><type>article</type><title>Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Virchow, J. Christian ; Mehta, Anish ; Ljungblad, Li ; Mitfessel, Harald</creator><creatorcontrib>Virchow, J. Christian ; Mehta, Anish ; Ljungblad, Li ; Mitfessel, Harald ; the MONICA study group ; MONICA study group</creatorcontrib><description>Summary Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting β2 -agonists (LABA) or both, necessitating additional treatment. Patients ≥18 years ( n = 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS + LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1 /PEF. Mean ACT scores improved from 14.6 ± 4.6 (baseline) to 19.4 ± 4.4 (month 6; p < 0.0001). Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively); the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma at baseline increased at month 6 (47.5 and 11.4%, respectively). The mini-AQLQ score (mean ± SD) improved from 4.0 ± 1.1 to 5.3 ± 1.1 ( p < 0.0001); FEV1 increased from 2.46 ± 0.89 to 2.60 ± 0.92 L ( p < 0.0001). Treatment with montelukast was generally well tolerated. In patients insufficiently controlled with ICS or ICS + LABAs, daily add-on montelukast improved both asthma control and asthma-related quality of life. Clinicaltrials.gov registry number NCT00802789.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1016/j.rmed.2009.11.022</identifier><identifier>PMID: 20031382</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Acetates - administration & dosage ; Add-on therapy ; Adrenergic beta-Agonists - administration & dosage ; Adult ; Anti-Asthmatic Agents - administration & dosage ; Asthma ; Asthma - drug therapy ; Asthma - psychology ; Asthma therapy ; Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Clinical medicine ; Dose-Response Relationship, Drug ; Drug therapy ; Drug Therapy, Combination ; Female ; Humans ; Leukotriene receptor antagonist ; Male ; Medical sciences ; Middle Aged ; Montelukast ; Mortality ; Pneumology ; Prospective Studies ; Pulmonary/Respiratory ; Quality of Life - psychology ; Quinolines - administration & dosage ; Standard deviation ; Studies ; Surveys and Questionnaires ; Treatment Outcome ; Young Adult</subject><ispartof>Respiratory medicine, 2010-05, Vol.104 (5), p.644-651</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-6e099c6081882611945c786acf53011d7f42092f023b2362f2088d50b92f01eb3</citedby><cites>FETCH-LOGICAL-c578t-6e099c6081882611945c786acf53011d7f42092f023b2362f2088d50b92f01eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0954611109003862$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22789316$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20031382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Virchow, J. Christian</creatorcontrib><creatorcontrib>Mehta, Anish</creatorcontrib><creatorcontrib>Ljungblad, Li</creatorcontrib><creatorcontrib>Mitfessel, Harald</creatorcontrib><creatorcontrib>the MONICA study group</creatorcontrib><creatorcontrib>MONICA study group</creatorcontrib><title>Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>Summary Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting β2 -agonists (LABA) or both, necessitating additional treatment. Patients ≥18 years ( n = 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS + LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1 /PEF. Mean ACT scores improved from 14.6 ± 4.6 (baseline) to 19.4 ± 4.4 (month 6; p < 0.0001). Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively); the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma at baseline increased at month 6 (47.5 and 11.4%, respectively). The mini-AQLQ score (mean ± SD) improved from 4.0 ± 1.1 to 5.3 ± 1.1 ( p < 0.0001); FEV1 increased from 2.46 ± 0.89 to 2.60 ± 0.92 L ( p < 0.0001). Treatment with montelukast was generally well tolerated. In patients insufficiently controlled with ICS or ICS + LABAs, daily add-on montelukast improved both asthma control and asthma-related quality of life. Clinicaltrials.gov registry number NCT00802789.</description><subject>Acetates - administration & dosage</subject><subject>Add-on therapy</subject><subject>Adrenergic beta-Agonists - administration & dosage</subject><subject>Adult</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - psychology</subject><subject>Asthma therapy</subject><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Clinical medicine</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Leukotriene receptor antagonist</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Montelukast</subject><subject>Mortality</subject><subject>Pneumology</subject><subject>Prospective Studies</subject><subject>Pulmonary/Respiratory</subject><subject>Quality of Life - psychology</subject><subject>Quinolines - administration & dosage</subject><subject>Standard deviation</subject><subject>Studies</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt1q3DAQhU1paTZpX6AXRVBK2gu7I8k_ciiFZelPIG0uml4LWR6z3sj2RrIL-xB9547xpoFcFAQCne8MMzoTRa84JBx4_mGX-A7rRACUCecJCPEkWvFMilhCnj6NVlBmaZxzzk-i0xB2QGCawvPohCySSyVW0Z91XcdDz7qhH9FNtyaMrO3pmBrvJkNvB2ZJ84NzWDOSt51hezO22I9hRg3L49m9ZcMe-9iZCh0L41QfLtjNFtn36x__Kl_2bLP1Q99atl4qvSP5crN-vzheRM8a4wK-PN5n0a8vn2823-Kr669EXcU2K9QY5whlaXNQXClB85VpZguVG9tkEjiviyYVUIoGhKyEzEUjQKk6g2p-41jJs-h8qbv3w92EYdRdGyw6Z3ocpqALKcsUQBVEvnlE7obJ99Sc5iAzLqHgJVFioawfQvDY6L1vO-MPBOk5K73Tc1Z6zkpzrikrMr0-lp6qWbu33IdDwNsjYII1rvGmt2144EShSslz4j4uHNKX_W7R62ApHot169GOuh7a__fx6ZHdupYiMu4WDxge5tVBaNA_562alwpKalTlQv4FP1vEvQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Virchow, J. Christian</creator><creator>Mehta, Anish</creator><creator>Ljungblad, Li</creator><creator>Mitfessel, Harald</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>ASE</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study</title><author>Virchow, J. Christian ; Mehta, Anish ; Ljungblad, Li ; Mitfessel, Harald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-6e099c6081882611945c786acf53011d7f42092f023b2362f2088d50b92f01eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acetates - administration & dosage</topic><topic>Add-on therapy</topic><topic>Adrenergic beta-Agonists - administration & dosage</topic><topic>Adult</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - psychology</topic><topic>Asthma therapy</topic><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Clinical medicine</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Leukotriene receptor antagonist</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Montelukast</topic><topic>Mortality</topic><topic>Pneumology</topic><topic>Prospective Studies</topic><topic>Pulmonary/Respiratory</topic><topic>Quality of Life - psychology</topic><topic>Quinolines - administration & dosage</topic><topic>Standard deviation</topic><topic>Studies</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Virchow, J. Christian</creatorcontrib><creatorcontrib>Mehta, Anish</creatorcontrib><creatorcontrib>Ljungblad, Li</creatorcontrib><creatorcontrib>Mitfessel, Harald</creatorcontrib><creatorcontrib>the MONICA study group</creatorcontrib><creatorcontrib>MONICA study group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Virchow, J. Christian</au><au>Mehta, Anish</au><au>Ljungblad, Li</au><au>Mitfessel, Harald</au><aucorp>the MONICA study group</aucorp><aucorp>MONICA study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>104</volume><issue>5</issue><spage>644</spage><epage>651</epage><pages>644-651</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>Summary Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting β2 -agonists (LABA) or both, necessitating additional treatment. Patients ≥18 years ( n = 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS + LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1 /PEF. Mean ACT scores improved from 14.6 ± 4.6 (baseline) to 19.4 ± 4.4 (month 6; p < 0.0001). Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively); the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma at baseline increased at month 6 (47.5 and 11.4%, respectively). The mini-AQLQ score (mean ± SD) improved from 4.0 ± 1.1 to 5.3 ± 1.1 ( p < 0.0001); FEV1 increased from 2.46 ± 0.89 to 2.60 ± 0.92 L ( p < 0.0001). Treatment with montelukast was generally well tolerated. In patients insufficiently controlled with ICS or ICS + LABAs, daily add-on montelukast improved both asthma control and asthma-related quality of life. Clinicaltrials.gov registry number NCT00802789.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>20031382</pmid><doi>10.1016/j.rmed.2009.11.022</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2010-05, Vol.104 (5), p.644-651 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733940087 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acetates - administration & dosage Add-on therapy Adrenergic beta-Agonists - administration & dosage Adult Anti-Asthmatic Agents - administration & dosage Asthma Asthma - drug therapy Asthma - psychology Asthma therapy Biological and medical sciences Chronic obstructive pulmonary disease, asthma Clinical medicine Dose-Response Relationship, Drug Drug therapy Drug Therapy, Combination Female Humans Leukotriene receptor antagonist Male Medical sciences Middle Aged Montelukast Mortality Pneumology Prospective Studies Pulmonary/Respiratory Quality of Life - psychology Quinolines - administration & dosage Standard deviation Studies Surveys and Questionnaires Treatment Outcome Young Adult |
| title | Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T21%3A13%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Add-on%20montelukast%20in%20inadequately%20controlled%20asthma%20patients%20in%20a%206-month%20open-label%20study:%20The%20MONtelukast%20In%20Chronic%20Asthma%20(MONICA)%20study&rft.jtitle=Respiratory%20medicine&rft.au=Virchow,%20J.%20Christian&rft.aucorp=the%20MONICA%20study%20group&rft.date=2010-05-01&rft.volume=104&rft.issue=5&rft.spage=644&rft.epage=651&rft.pages=644-651&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1016/j.rmed.2009.11.022&rft_dat=%3Cproquest_cross%3E733940087%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1035130719&rft_id=info:pmid/20031382&rft_els_id=S0954611109003862&rfr_iscdi=true |